INOVIO's INO-3107 BLA Advances with PDUFA Date; Cash Runway Extended, Partner Data Positive

What happened

INOVIO reported Q2 2026 results with the FDA reviewing the BLA for INO-3107 for recurrent respiratory papillomatosis (RRP) and a PDUFA target action date of October 30, 2026. The company is advancing commercial preparations for a potential launch, while its partner ApolloBio reported positive topline results from a Phase 3 trial of VGX-3100 for cervical dysplasia in China. INOVIO also presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb) and DNA-Encoded Protein (DPROT) programs, but these remain early-stage. Cash, cash equivalents, and short-term investments are expected to fund operations into late first quarter 2027, which would cover a potential launch if approved. The update reduces near-term financing overhang but does not change the binary regulatory risk.

Implication

The assignment of a PDUFA date confirms the BLA is under substantive review, though approval is not assured given prior CMC/device challenges and a competitor already on the market. The extended cash runway into late Q1 2027 removes the immediate going-concern threat and suggests management has secured financing or reduced burn sufficiently to reach the decision date. Positive Phase 3 data from VGX-3100 in China provides optionality but does not directly bolster INO-3107's case since it is a different asset and indication. Investors should monitor FDA communications for any signs of CMC or device deficiencies, which have been historical risk areas. A positive outcome could drive significant re-rating, while a Complete Response Letter would likely pressure the stock given limited alternate near-term catalysts.

Thesis delta

Previously NEUTRAL/HOLD due to financing overhang and lack of BLA acceptance. Now with a PDUFA date of October 30, 2026 and cash into late Q1 2027, the path to a regulatory decision is clearer, reducing near-term downside risk. The stance shifts to SPECULATIVE BUY/HOLD given the binary outcome but improved odds of reaching the finish line.